SLXN - Utang jangka dawa silexion.com

Future revenues for Silexion Therapeutics Corp (SLXN) rely on the market launch of siRNA drugs to combat KRAS mutations and pancreatic cancer. This chart of current market value reflects long-term debts, which currently stand at 0.00. A lack of profitability and pricing power leaves the company dependent on the confirmed efficacy of RNA therapy. Financial stability is based exclusively on external investments to conduct clinical trials.

Silexion Therapeutics Corp (SLXN) is investing substantial resources into AI modeling and RNA therapy for oncological diseases. The corporation's long-term debt captures the total volume of credit obligations with maturities exceeding one year. This trend reflects the actual cost of borrowed capital without market noise. Trend analysis allows for an assessment of the funding stability for R&D cycles. Investor consensus links the growth of this metric to the expansion of the business's technological potential.